Pinealon Dosage Guide: Protocols, Calculator & Safety

Beginner-level Pinealon use follows the pulsed dosing convention that is standard across most Khavinson peptide protocols — short daily or alternate-day courses rather than continuous long-term dosing. The rationale, per Khavinson's published framework, is that short peptide bioregulators act on tissue through pulses that trigger durable gene expression changes persisting beyond the dosing window.

Beginner Pinealon protocol (conservative):

• Route: subcutaneous injection (most common) or intranasal (less common but documented)
• Subcutaneous dose: 2–5 mg per day
• Course length: 10–20 days per cycle
• Frequency of cycles: 2–4 times per year
• Timing: morning or early afternoon, typically avoiding late evening to minimize sleep disruption

Beginner intranasal alternative:

• Intranasal dose: 150–300 mcg per nostril per administration
• Frequency: once daily
• Course length: 10–20 days per cycle

Beginner first-cycle recommendations:

1. Source from a reputable supplier with a certificate of analysis showing peptide purity (typically ≥98%) and correct molecular weight for Glu-Asp-Arg (432.4 g/mol)
2. Store the powder refrigerated in a sealed container, protected from light
3. Reconstitute with bacteriostatic water following standard peptide protocol (see reconstitution notes)
4. Start at the lower end of the dose range (2 mg subcutaneous or 150 mcg/nostril intranasal) for the first course
5. Administer consistently at the same time of day across the cycle
6. Document subjective effects — cognitive clarity, sleep, mood, energy — daily in a simple log
7. Complete a full 10-day course before assessing response
8. Take a 60–90 day break after the course before considering a repeat

What to expect:

• Subjective effects often reported include improved mental clarity, slightly better sleep, and mild energy improvement
• Effects are typically subtle, not dramatic — dramatic reports are often unreliable
• Effects may persist for weeks to months after the course ends, consistent with the pulsed dosing theory
• No visible effects are common, especially in the first cycle, and do not indicate the compound is ineffective

Beginner supplies needed:

• Pinealon lyophilized powder (usually supplied in 5–10 mg vials)
• Bacteriostatic water for reconstitution
• Insulin syringes (29–31 gauge, 0.3–1 mL) for subcutaneous administration, or nasal spray bottle for intranasal
• Alcohol swabs
• Sharps disposal container
• Log for documenting subjective effects

Beginner safety practices:

• Clean injection site with alcohol swab before each use
• Rotate injection sites (abdomen, thigh, upper arm) to minimize localized sensitivity
• Inspect reconstituted solution for clarity before each injection
• Store reconstituted peptide refrigerated and use within 30 days of reconstitution
• Stop immediately and seek evaluation for any significant adverse symptoms

What beginners often do wrong:

• Expecting dramatic, obvious effects. Pinealon's claimed effects are subtle and cumulative. Expecting a "brain feeling" like caffeine or modafinil is unrealistic.
• Stacking too many peptides on first cycle. Introduce Pinealon alone to understand its effects before adding other Khavinson peptides.
• Ignoring source quality. Research-chemical peptide supply chains are variable. Using an unverified source can produce either no effect or unpredictable effects.
• Dosing too frequently. Daily dosing for months without break is not the Khavinson protocol. Pulse dosing with long washouts is the pattern.
• Overinterpreting placebo-driven effects. Subjective improvement in the first few days is often placebo; meaningful effects are typically evaluated at week 2–3 and in the months after the cycle.

What a successful beginner cycle looks like:

• Purchased from a reputable source with CoA
• Reconstituted and administered correctly
• 10-day subcutaneous course at 2–3 mg/day
• Mild subjective cognitive and sleep improvement noted during and for several weeks after
• No adverse effects
• Considered for repeat at 60–90 days

For readers completely new to peptide self-administration, the more pragmatic first step is to start with something simpler — oral adaptogen compounds, nutritional optimization, exercise, and sleep — before introducing injectable research peptides. Pinealon is a reasonable next-step for readers who have already committed to peptide protocols (BPC-157, GHK-Cu, or similar) and want to add a cognitive-aging-focused compound.

Intermediate Pinealon users are typically those who have completed 1–3 introductory cycles, are comfortable with self-administration, and want to optimize dose, timing, and stack composition. At this level, users often pair Pinealon with other Khavinson peptides and begin integrating it into a broader longevity and cognitive protocol.

Intermediate dosing conventions:

• Subcutaneous dose: 3–7 mg per day
• Intranasal dose: 300–500 mcg per nostril per administration, 1–2 times daily
• Course length: 15–20 days per cycle
• Cycles per year: 3–4, typically quarterly
• Timing: morning preferred; some users split the dose into morning and midday administrations at half-dose each

Intermediate stacking approaches:

Cognitive and longevity stack:

• Pinealon (subcutaneous, 5 mg/day, 20 days)
• Epitalon (subcutaneous, 5–10 mg/day, 10 days) — often run in the same cycle window or alternating cycles
• Semax intranasal daily or as-needed for acute cognitive load
• NAD+ precursors daily throughout the cycle
• Nutritional cofactors: omega-3 EPA/DHA, vitamin D, B-complex

Circadian and sleep stack:

• Pinealon 5 mg subcutaneous in the morning, 15 days
• DSIP 0.1 mg subcutaneous at bedtime as needed
• Melatonin 0.3–1 mg at bedtime if circadian disruption
• Magnesium glycinate, glycine

General anti-aging stack:

• Pinealon cycle
• Epitalon cycle (alternating or overlapping)
• Thymalin or Thymogen cycle (immune support layer)
• Rapamycin if already part of user's protocol
• Metformin if indicated
• Foundation supplements

Intermediate monitoring:

• Baseline labs (before starting cycles): CBC, CMP, lipid panel, A1c, thyroid panel, testosterone or estrogen as appropriate, vitamin D, B12, ferritin, inflammatory markers (hs-CRP)
• Subjective tracking: Weekly cognitive self-rating (e.g., PSS, mood scales), sleep quality, energy, physical performance
• Objective tracking (if available): Heart rate variability trends, sleep architecture from wearable, cognitive testing (online tools like CANTAB or Dual N-Back scores)
• Annual re-labs: Full panel repeat; consider hormone panel changes, inflammation markers

Intermediate cycle structures:

Pattern A — Sequential quarterly cycles:

• Q1: Pinealon 20-day cycle
• Q2: Epitalon 10-day cycle
• Q3: Pinealon 20-day cycle
• Q4: Thymogen or Thymalin cycle

Pattern B — Integrated cycles:

• Pinealon + Epitalon together for 10 days, repeat quarterly
• Other Khavinson peptides rotated through as individual cycles between

Pattern C — Chronic intranasal low-dose:

• Daily intranasal Pinealon at 300 mcg/nostril for 3–6 months continuous
• Lower dose, longer duration; less well-documented in classical Khavinson protocol but used by some body-hackers

Intermediate dose adjustment based on response:

• If no subjective response after 2 full cycles: increase dose to 7 mg/day or extend cycle to 20 days; consider verifying product purity
• If response is good: maintain the successful protocol; do not escalate unnecessarily
• If response is initially positive then fades: this is expected; it reflects pulsed-dosing biology; schedule next cycle at standard interval
• If side effects emerge: reduce dose, separate in time from other peptides, or discontinue and reassess

Intermediate stacking cautions:

• Do not exceed 3 Khavinson peptides simultaneously without experience managing each individually
• Space injections to different body sites if running multiple peptides concurrently
• Maintain dose records; with multiple cycling peptides, it becomes easy to lose track
• Watch for cumulative sleep effects if multiple peptides affect circadian signaling

Intermediate lab-based optimization:

• If hs-CRP is elevated — consider adding Thymalin or Thymogen to address inflammation alongside Pinealon
• If lipid profile worsening — consider Ventfort or Cartalax vascular peptides
• If signs of metabolic dysregulation — Metformin, GLP-1 agonists, or lifestyle intervention before adding more peptides

Pairings with training and lifestyle:

• Cognitive challenge during Pinealon cycles — new learning, complex problem-solving — to potentially amplify neuroplasticity effects
• Sleep prioritization — protect 8 hours consistently during peptide cycles
• Stress management — don't start a peptide cycle during high-stress periods when sleep and recovery are compromised
• Light exposure management — morning bright light, evening dim light; supports pineal function

When to escalate to advanced level:

• After 4+ successful intermediate cycles
• With stable lab trends supporting continued use
• With user's ability to document and interpret subjective and objective response data
• With access to more advanced compounds like rapamycin, high-dose NAD+ protocols, or specialized Khavinson combinations

When to step back:

• Lack of benefit after 4+ cycles
• Lab trends that suggest harm (inflammation rising, markers worsening)
• New health conditions that complicate the peptide stack
• Change in risk tolerance or priorities

The intermediate level is where most serious Pinealon users stabilize. The advanced level introduces more stacking complexity and risk without necessarily more benefit for most users.

Advanced Pinealon use is typically characterized by multi-year engagement, integration with clinical biomarker monitoring, combination with experimental longevity interventions, and often participation in specialized gerontology communities (formal or informal) that exchange protocols and results.

Advanced dosing and cycle conventions:

• Subcutaneous dose: 5–10 mg per day
• Split dosing: some advanced users split into 2.5 mg twice daily for more sustained effect
• Intranasal dose: 500–800 mcg/nostril twice daily
• Course length: 20–30 days per cycle
• Cycles per year: 3–4, with specific sequencing and stack coordination
• Long-duration low-dose variants: some advanced users run intranasal Pinealon continuously at low dose for 3–6 months

Advanced stacking — full Khavinson peptide rotation:

A comprehensive Khavinson rotation, typical of advanced user protocols, may look like:

• Month 1: Pinealon (brain) + Epitalon (pineal/telomere)
• Month 2: Thymalin or Thymogen (thymus/immunity) + Vilon (general immunity)
• Month 3: Cartalax (cartilage) + Ventfort (vascular)
• Month 4: Prostamax or Testagen (reproductive system) + Bronchogen (respiratory)
• Month 5: Livagen (liver) + Cardiogen (heart)
• Month 6–12: Rotation continues, with repeat of priority peptides

This is a highly committed and expensive protocol, and its rationale is to cycle through tissue-specific regulation across all major organ systems annually. Its evidence base is Khavinson's overall clinical framework rather than head-to-head efficacy data.

Advanced integration with broader longevity interventions:

• Rapamycin — weekly or biweekly dosing for mTOR inhibition
• Metformin — daily if metabolic health warrants
• NAD+ precursors + glutathione — daily foundation
• Semaglutide or tirzepatide — if metabolic indication
• Hormone replacement — testosterone, estrogen, DHEA as appropriate and medically managed
• Senolytic cycles — FOXO4-DRI, dasatinib/quercetin; periodic rather than continuous
• Exercise mimetics — for users interested in the metabolic exercise-mimetic space
• Mitochondrial uncouplers — for very experienced users willing to accept research-chemical risk

Advanced biomarker and monitoring panel:

• Baseline and semi-annual comprehensive metabolic panel
• Inflammatory markers: hs-CRP, IL-6, TNF-alpha, homocysteine
• Metabolic markers: fasting glucose, insulin, HOMA-IR, A1c, lipid panel with advanced particles (ApoB, Lp(a))
• Hormonal panel: testosterone (total, free, bioavailable), estradiol, cortisol rhythm, thyroid full, DHEA-S, IGF-1
• Cardiovascular: high-sensitivity troponin, NT-proBNP if indicated, lipid particle analysis, CIMT or CAC if indicated
• Cancer screening: age- and sex-appropriate, generally more aggressive given long-term peptide use without safety data
• Cognitive testing: formal neuropsychological battery annually
• Imaging: brain MRI if warranted by symptoms or family history
• Biological age measures: epigenetic clock (DunedinPACE, Horvath), inflammatory age markers

Advanced cycle coordination considerations:

• Time Pinealon cycles around major cognitive or psychological demands (e.g., intensive learning periods, performance events)
• Avoid starting peptide cycles during major life stressors (poor sleep, illness) — cycles should be run in stable periods
• Coordinate with other pharmacologic interventions — don't start rapamycin and a new peptide in the same week
• Plan ahead for supply — reputable peptide suppliers can have weeks-long lead times

Advanced individualization:

• Genetic considerations — some users with specific APOE4 or other neurodegeneration-risk genotypes may weight neuroprotective peptides differently
• Medical history weighting — family history of Alzheimer's or cognitive decline may justify longer or more frequent Pinealon cycles
• Sport and performance — some users integrate peptide cycles with training periodization, though Pinealon is not on WADA's prohibited list so it is not a direct sport issue
• Sleep and circadian — users with circadian rhythm disorders may benefit from Pinealon in a specific morning-dose pattern to restore rhythm

Advanced risks to manage:

• Cumulative research-chemical exposure — multi-year continuous engagement with unapproved peptides carries aggregate unknowns
• Financial cost — Khavinson peptide stacks run several thousand dollars annually
• Supply chain dependency — quality control concerns grow with long-term reliance on research-chemical sources
• Over-reliance on pharmacology vs. lifestyle — advanced users occasionally neglect exercise, sleep, and nutrition while chasing peptide optimization; this is a mistake

Advanced decision-making framework:

Advanced users should periodically ask:

• Am I seeing durable benefit from this protocol, or am I cycling through peptides hoping for something novel?
• Are my biomarkers trending in favorable directions?
• Is my subjective cognitive and physical status improving, stable, or deteriorating?
• Have I maintained the lifestyle foundations (sleep, training, nutrition, stress management, relationships)?
• Is the research-chemical risk budget justified by the benefit?

When the answer to the above questions suggests the protocol is not delivering value, advanced users are often best served by narrowing rather than expanding their peptide stack — focusing on the 1–2 peptides with the clearest subjective and biomarker response, and abandoning the rest.

When to scale back:

• Biomarker worsening despite adherent use
• Plateau in response and no new meaningful benefit
• Rising cost-benefit concerns
• Life circumstances that make careful execution difficult

Advanced Pinealon use is, ultimately, an expression of a particular worldview about aging and intervention. For readers who find the Khavinson framework compelling and can execute the monitoring infrastructure, a multi-year commitment to a Pinealon-containing stack is defensible. For readers who prefer stronger evidence bases, staying at the beginner or intermediate level (or switching to more Western-validated interventions) is equally defensible.